Spire Wealth Management Catalyst Pharmaceuticals, Inc. Transaction History
Spire Wealth Management
- $3.01 Billion
- Q1 2024
A detailed history of Spire Wealth Management transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Spire Wealth Management holds 1,038 shares of CPRX stock, worth $16,400. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,038
Previous 1,038
-0.0%
Holding current value
$16,400
Previous $17,000
5.88%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding CPRX
# of Institutions
277Shares Held
95.7MCall Options Held
40.6KPut Options Held
67.2K-
Black Rock Inc. New York, NY17.7MShares$280 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY9.13MShares$144 Million3.01% of portfolio
-
State Street Corp Boston, MA8.15MShares$129 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.98MShares$126 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.74MShares$43.3 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $1.62B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...